Advertisement
BDTX vs MLTX
Which Stock Would AI Choose? Black Diamond Therapeutics (BDTX) vs. MoonLake Immunotherapeutics (MLTX) Stock Comparison
Key Takeaways
- Both BDTX and MLTX are clinical-stage, pre-revenue biotechnology companies, yet they pursue different diseases: oncology versus inflammatory conditions.
- BDTX is a micro-cap precision-oncology name trading near its 52-week low and centered almost entirely on a single lead asset, silevertinib.
- MLTX carries a larger market capitalization (roughly $1 billion) and sits closer to a near-term regulatory catalyst for its lead candidate, sonelokimab.
- Relative performance has diverged sharply: MLTX has rebuilt momentum after a prior drawdown, while BDTX has remained under pressure despite positive clinical data.
- For more detail on breaking developments and daily price action, explore BDTX Major News and BDTX Today's Price Move, as well as MLTX Major News and MLTX Today's Price Move.
- To see how automated systems are currently positioning across the market, explore Trending AI Robots.
Introduction
Clinical-stage biotechnology stocks share a common profile: no product revenue, heavy reliance on pipeline catalysts, and valuations driven by clinical and regulatory milestones rather than earnings. Comparing BDTX and MLTX offers a useful study in how two pre-commercial drug developers with similar financial structures can occupy very different positions in the market. This stock comparison is most relevant to investors and traders who follow high-risk, high-reward biotech names, track clinical catalysts, and want to assess market positioning across contrasting therapeutic areas. Understanding the differences in pipeline concentration, cash runway, and sentiment can help frame the trade-offs between these two speculative equities.
BDTX Overview and Recent Performance
Black Diamond Therapeutics (BDTX) is a clinical-stage oncology company advancing "MasterKey" therapies designed to target families of oncogenic mutations. Its lead program is silevertinib, a brain-penetrant, fourth-generation EGFR (epidermal growth factor receptor) inhibitor being studied in EGFR-mutant non-small cell lung cancer (NSCLC) and EGFRvIII-positive glioblastoma (GBM). In recent weeks, the company reported Phase 2 frontline NSCLC data showing a 15.2-month median progression-free survival (PFS), a 60% overall response rate (ORR), and strong central nervous system (CNS) activity. Despite these results, the stock has remained subdued, reflecting investor concerns about a single-asset pipeline, entrenched competition from larger EGFR therapies, and an early-stage dataset. The company ended a recent quarter with roughly $118 million in cash, which management expects to fund operations into the second half of 2028.
MLTX Overview and Recent Performance
MoonLake Immunotherapeutics (MLTX) is a clinical-stage biotechnology company focused on inflammatory diseases. Its lead candidate, sonelokimab (SLK), is a tri-specific Nanobody being developed for hidradenitis suppurativa (HS), a chronic inflammatory skin condition, with additional programs in other inflammatory indications. Recent market activity has been shaped by regulatory progress: following a U.S. FDA (Food and Drug Administration) Type B meeting, the company aligned on a Biologics License Application (BLA) submission targeted for the third quarter of 2026. The stock has experienced sharp swings over the past year, including a steep drawdown on prior mixed trial results, followed by a rebound as the regulatory pathway clarified. Analysts remain broadly positive, with a consensus Buy rating and price targets well above recent trading levels, though execution, funding, and concentration on a single asset remain key considerations.
Trending AI Robots
Tickeron maintains hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only a curated selection earns a place in the Trending AI Robots section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the specific set of tickers they trade, and the platform highlights only those currently best suited to prevailing market conditions. This filtering can help traders cut through a crowded field and focus on automated systems whose recent behavior aligns with today's environment. Readers interested in applying systematic, data-driven approaches to names like BDTX and MLTX can explore the Trending AI Robots page to review available strategies and statistics.
Head-to-Head Comparison
The two companies diverge most clearly in therapeutic focus and stage of development. BDTX operates in precision oncology, where competition from established EGFR inhibitors is intense and differentiation must be proven in larger studies. MLTX operates in immunology and dermatology, where the commercial opportunity in HS is substantial but still hinges on regulatory approval and eventual market uptake. In terms of market positioning, MLTX has a meaningfully larger market capitalization and stronger analyst conviction, while BDTX trades near its lows with a smaller capitalization and a more concentrated risk profile. On catalysts, MLTX has a clearer near-term regulatory milestone in its planned BLA submission, whereas BDTX's value creation leans on clinical readouts and an anticipated FDA meeting to define a pivotal path. Both carry funding and execution risk, but their relative momentum and sentiment profiles differ considerably.
Tickeron AI Verdict
Based on observable factors such as trend consistency, near-term catalysts, analyst positioning, and relative momentum, Tickeron's AI would likely lean toward MLTX at present. The combination of a clarified regulatory pathway, a larger market capitalization, stronger consensus sentiment, and a recent rebound in price momentum presents a comparatively more favorable positioning than BDTX's micro-cap, single-asset profile trading near its 52-week low. That said, this assessment reflects probabilistic weighting of current signals rather than a definitive forecast, and the concentrated, high-risk nature of both clinical-stage companies means the relative outlook could shift quickly with new data or regulatory developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDTX is a Hold and MLTX is a StrongBuy.
BDTX's RSI Indicator ascending out of oversold territory
The RSI Indicator for BDTX moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 29 of the 34 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +12.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDTX advanced for three days, in 199 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BDTX as a result. In 60 of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for BDTX turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 38 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
BDTX moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
BDTX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BDTX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.037) is normal, around the industry mean (3.498). P/E Ratio (-2.313) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.360) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. BDTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MLTX in upward trend: price rose above 50-day moving average on November 09, 2026
MLTX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 40 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MLTX's RSI Oscillator exited the oversold zone, 11 of 16 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on MLTX as a result. In 83 of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for MLTX just turned positive on October 20, 2026. Looking at past instances where MLTX's MACD turned positive, the stock continued to rise in 42 of 53 cases over the following month. The odds of a continued upward trend are 79%.
The 10-day moving average for MLTX crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +16.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLTX advanced for three days, in 257 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
MLTX broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MLTX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.292) is normal, around the industry mean (3.498). P/E Ratio (-3.003) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. MLTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
BDTX | MLTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 41 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | 38 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 95 | |
SMR RATING 1..100 | 97 | 98 | |
PRICE GROWTH RATING 1..100 | 80 | 58 | |
P/E GROWTH RATING 1..100 | 98 | 12 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDTX's Valuation (31) in the null industry is in the same range as MLTX (38). This means that BDTX’s stock grew similarly to MLTX’s over the last 12 months.
MLTX's Profit vs Risk Rating (95) in the null industry is in the same range as BDTX (100). This means that MLTX’s stock grew similarly to BDTX’s over the last 12 months.
BDTX's SMR Rating (97) in the null industry is in the same range as MLTX (98). This means that BDTX’s stock grew similarly to MLTX’s over the last 12 months.
MLTX's Price Growth Rating (58) in the null industry is in the same range as BDTX (80). This means that MLTX’s stock grew similarly to BDTX’s over the last 12 months.
MLTX's P/E Growth Rating (12) in the null industry is significantly better than the same rating for BDTX (98). This means that MLTX’s stock grew significantly faster than BDTX’s over the last 12 months.
| BDTX | MLTX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 85% | 1 day ago 69% |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 83% |
| Momentum ODDS (%) | 1 day ago 87% | 1 day ago 78% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 79% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 88% | 1 day ago 87% |
| Advances ODDS (%) | 4 days ago 83% | 4 days ago 84% |
| Declines ODDS (%) | 11 days ago 90% | 8 days ago 80% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 84% |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDTX’s FA Score shows that 1 FA rating(s) are green while MLTX’s FA Score has 1 green FA rating(s).
- BDTX’s FA Score: 1 green, 4 red.
- MLTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDTX’s TA Score shows that 3 TA indicator(s) are bullish while MLTX’s TA Score has 6 bullish TA indicator(s).
- BDTX’s TA Score: 3 bullish, 6 bearish.
- MLTX’s TA Score: 6 bullish, 4 bearish.
Price Growth
BDTX (@Biotechnology) experienced а -15.26% price change this week, while MLTX (@Biotechnology) price change was +16.87% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
BDTX is expected to report earnings on Mar 24, 2027.
MLTX is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
MLTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, MLTX has been closely correlated with KALA. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if MLTX jumps, then KALA could also see price increases.
| Ticker / NAME | Correlation To MLTX | 1D Price Change % | ||
|---|---|---|---|---|
| MLTX | 100% | +7.56% | ||
| KALA - MLTX | 82% Closely correlated | N/A | ||
| CGON - MLTX | 50% Loosely correlated | -0.04% | ||
| ELVN - MLTX | 47% Loosely correlated | -0.02% | ||
| XENE - MLTX | 44% Loosely correlated | +1.72% | ||
| BDTX - MLTX | 42% Loosely correlated | +0.94% | ||
More | ||||